Referenzen
Produkte Transfektion
Kostenlose Testsamples
Anwendungshinweise:
Im „Transfection Reagent Selection Guide“ können Sie durch Filterfunktionen z.B. für Ihre Kombination aus zu transfizierender Zelle und Nukleinsäure die Liste vorhandener Referenzen durchsuchen. Ebenso können Sie im Feld „Referenzen durchsuchen“ am Anfang der Seite mit passenden Schlagwörtern zu einem Ergebnis gelangen. Eine Referenz zeigt an, dass das gefundene Transfektionsreagenz bereits erfolgreich für die entsprechende Anwendung verwendet wurde. Im Idealfall sind getestete Transfektionsparameter und Transfektionseffizienzen angegeben.
Keine Referenz? > Allgemeine Auswahlhilfe
Wenn Sie keine Referenz gefunden haben, heißt das nicht, dass kein passendes Reagenz zur Verfügung steht, sondern lediglich, dass bisher keine Erfahrungsberichte vorliegen. In diesem Falle kann durch eine Vorauswahl ein erfolgsversprechendes Transfektionsreagenz ausgewählt (Allgemeine Auswahlhilfe) und letztendlich ausgetestet (Kostenlose Testsamples) werden. Wenn Sie einen Erfahrungsbericht für uns schreiben möchten machen wir Ihnen ein Angebot für eine Gegenleistung.
CELL TYPE | DESCRIPTION OF CELL TYPE | CAT.NO. | SPECIES | ORIGIN OF CELLS | COMMON CELL TYPE | GROWTH PROPERTIES | NUCLEIC ACID / DELIVERED MOLECULE | APPLICATION | PRODUCT | REFERENCE TYPE | BIBLIOGRAPHIC DATA | LINK | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Flp-In TREx HeLa |
Human cervix adenocarcinoma cell line (derivative of HeLa) | Human | genital tract | cell line | adherent | plasmid | CRISPR | Metafectene PRO | publication | T. M. Nthiga et al., The EMBO J., 39: e103649, DOI 10.15252/embj.2019103649 | Link | ||
Flp-In TREx HeLa |
Human cervix adenocarcinoma cell line (derivative of HeLa) | Human | genital tract | cell line | adherent | plasmid | stable transfection | Metafectene PRO | publication | T. M. Nthiga et al., The EMBO J., 39: e103649, DOI 10.15252/embj.2019103649 | Link | ||
Gsalpha |
Human prostate cancer cell line that overexpresses the Gs-alpha protein (derivat of PC3) | Human | genital tract | cell line | adherent | plasmid | RNA-Interference | Metafectene | publication | K. A. Iczkowski et al., Mol Biotechnol, Oct 2004; 28(2): 97-103 | |||
Gsalpha |
Human prostate cancer cell line that overexpresses the Gs-alpha protein (derivat of PC3) | Human | genital tract | cell line | adherent | plasmid | RNA-Interference | Metafectene | publication | A. L. Omara-Opyene et al., Lab Invest., 2004 Jul; 84(7):894-907 | |||
Gsalpha-QL |
Human prostate cancer cell line that overexpresses the Gs-alpha protein (derivat of PC3) | Human | genital tract | cell line | adherent | plasmid | RNA-Interference | Metafectene | publication | K. A. Iczkowski et al., Anticancer Res, Jul 2006; 26: 2863 - 2872 | Link | ||
HEC-1A |
Human endometrial carcinoma cell line | ATCC HTB-112 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | H. Kiaris et al., PNAS, Aug 2003; 100: 9512 - 9517 | Link | ||
HEK293 |
Human embryonic kidney cell line | ATCC CRL-1573 | Human | genital tract | cell line | adherent | plasmid | cotransfection (plasmid/plasmid) | Metafectene PRO | publication | J. Elvenes et al., PLoS ONE, 2011, 6(9): e24659, doi:10.1371/journal.pone.0024659 | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | stable transfection | Metafectene | application note | |||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene PRO | publication | V. De Leo et al., Toxicol. Res., 2017, 6: 947, DOI: 10.1039/c7tx00172 | |||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | siRNA | RNA-Interference | Metafectene | publication | V. Mikat et al., RNA, Dec 2007; 13: 2341 - 2347 | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene PRO | publication | K. Estrada, JAMA, 2014, 311(22): 2305-2314; doi:10.1001/jama.2014.6511 | |||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | application note | ||||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | K2 Transfection System | publication | I. Sargiannidou et al., Neurogenetics, 2015, DOI 10.1007/s10048-015-0442-4 | |||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | stable transfection | Metafectene | publication | C. T. Hellwig et al., J. Biol. Chem., Aug 2008; 283: 21676 - 21685 | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | K. Konopka et al., Cell Mol Biol Lett, Jan 2009; 14(1): 70-89 | |||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene EASY | application note | ||||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | J. Arias-del-Val, Cell Calcium, 2019, 77: 68–76, doi.org/10.1016/j.ceca.2018.12.004 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | siRNA | cotransfection (plasmid/siRNA) | Metafectene | publication | X. M. M. Weyel, Dissertation, 2018, Goethe- Universität in Frankfurt am Main | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | bacmid | stable transfection | Metafectene PRO | publication | C. Heissenberger et al., Nucleic Acids Res., 2019, 47, 22: 11807–11825, doi: 10.1093/nar/gkz1043 | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | Z. Knust et al., Infect. Immun., May 2009; 77: 1835 - 1841 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | cotransfection (plasmid/siRNA) | K2 Transfection System | application note | |||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene PRO | application note | ||||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene PRO | application note | ||||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | L. Rampoldi et al., Hum. Mol. Genet., Dec 2003; 12: 3369 - 3384 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | CRISPR | Metafectene PRO | publication | S. Kumar et al., Dev. Cell., 2019, 49(1): 130–144.e6., doi:10.1016/j.devcel.2019.01.027. | Link |